{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:57:01Z","timestamp":1783400221707,"version":"3.54.6"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:p>This study aims to investigate antiviral effectiveness, side effects, and disease outcomes in patients who have been using entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for a long-term in chronic hepatitis B. Patients with chronic hepatitis B who had been using TDF or ETV for at least 10 years were included in this retrospective study. Co-infected patients, those receiving immunosuppressive therapy, and transplant patients were excluded. Of the study\u2019s total 173 patients (baseline mean age 43.4\u2005\u00b1\u200511.7 years), 110 (63.6%) were men. Thirty-three (19.1%) patients were cirrhotic, and hepatitis B e-antigen was negative in 131 (75.7%) patients at the baseline. Ninety-two (53.2%) patients used TDF and 81 (46.8%) used ETV for a mean of 156.76\u2005\u00b1\u200521.60 (120\u2013204) months. Hepatitis B virus (HBV)-DNA negativity (&lt;10 IU\/mL) was achieved in 97.7% of all patients. Biochemical remission was achieved in 98.3% of all patients at the last visit. HBsAg became negative in only 5 (2.9%). Hepatocellular carcinoma (HCC) developed in 9 (5.2%) patients. All HCCs occurred after the 5th year of treatment. The age at HBV diagnosis was higher in HCC patients (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.023), but the most important risk factor for the development of HCC was to have cirrhosis at baseline. Eight (4.6%) patients died in the follow-up, and 2 were due to liver disease and the remaining non-liver disease. At the end of follow-up, HBV-DNA negativity was achieved in almost all patients, and HBsAg sero-clearance was rarely achieved. Very few patients developed HCC and the long-term mortality rate was similar to the general population.<\/jats:p>","DOI":"10.1097\/md.0000000000042766","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:02:04Z","timestamp":1749502924000},"page":"e42766","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Results in chronic hepatitis B patients using tenofovir and entecavir for at least 10 years; HBV clearance rare, disease outcomes good: An observational cohort study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-2660","authenticated-orcid":false,"given":"Z\u00fclal","family":"\u0130stemihan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Keme\u00e7","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timurhan","family":"Cebeci","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okan","family":"\u00c7etin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezen","family":"Gen\u00e7 Ulu\u00e7e\u00e7en","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynure","family":"R\u00fcstemzade","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanan","family":"Nuriyev","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilger","family":"\u00c7avu\u015f","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"\u00c7ifciba\u015fi \u00d6rmeci","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz","family":"Aky\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Be\u015fi\u015fik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahattin","family":"Kaymako\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013.","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/jvh.13843","article-title":"Cost-effectiveness of treating all hepatitis B-positive individuals in the United States.","volume":"30","author":"Razavi-Shearer","year":"2023","journal-title":"J Viral Hepat"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B.","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"e6336","DOI":"10.1097\/MD.0000000000006336","article-title":"Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT \u2264 2 ULN: a retrospective cohort study.","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/jvh.12279","article-title":"APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS).","volume":"21","author":"Teshale","year":"2014","journal-title":"J Viral Hepat"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jvh.12224","article-title":"The validity of serum markers for fibrosis staging in chronic hepatitis B and C.","volume":"21","author":"Li","year":"2014","journal-title":"J Viral Hepat"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection.","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3 Suppl 4","key":"R10-20250609","first-page":"1","article-title":"Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice.","volume":"7","author":"Afdhal","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2012.01.044","article-title":"Effectiveness of hepatitis B treatment in clinical practice.","volume":"142","author":"Scaglione","year":"2012","journal-title":"Gastroenterology"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12664-015-0576-1","article-title":"Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.","volume":"34","author":"Goyal","year":"2015","journal-title":"Indian J Gastroenterol"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"e13983","DOI":"10.1097\/MD.0000000000013983","article-title":"Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-na\u00efve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials.","volume":"98","author":"Cai","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"R14-20250609","first-page":"666","article-title":"Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China.","volume":"8","author":"Huang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development.","volume":"73","author":"Tout","year":"2020","journal-title":"J Hepatol"},{"key":"R16-20250609","doi-asserted-by":"crossref","first-page":"e00046","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy.","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"R17-20250609","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/jvh.12358","article-title":"Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-na\u00efve chronic hepatitis B patients in the real-world setting.","volume":"22","author":"Idilman","year":"2015","journal-title":"J Viral Hepat"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2009.07.009","article-title":"Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.","volume":"51","author":"Wu","year":"2009","journal-title":"J Hepatol"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1016::AID-CNCR10>3.0.CO;2-V","article-title":"Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma.","volume":"88","author":"Kubo","year":"2000","journal-title":"Cancer"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/apt.16197","article-title":"Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF\/ANRS CO22 Hepather cohort.","volume":"53","author":"Pol","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.3748\/wjg.v11.i13.1976","article-title":"Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey.","volume":"11","author":"Sunbul","year":"2005","journal-title":"World J Gastroenterol"},{"key":"R22-20250609","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"R23-20250609","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3748\/wjg.v28.i6.665","article-title":"Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.","volume":"28","author":"Gokcen","year":"2022","journal-title":"World J Gastroenterol"},{"key":"R24-20250609","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12876-023-03027-4","article-title":"Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"R25-20250609","first-page":"189","article-title":"Restriction fragment length polymorphism analysis and direct sequencing for determination of HBV genotypes in a Turkish population.","volume":"31","author":"Sertoz","year":"2008","journal-title":"New Microbiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:02:08Z","timestamp":1749502928000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":25,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042766","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}